DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Ultrasensitive Detection of Toxins Using Immunoassay Amplification. Phase 1
Final rept. 15 Jul 91-15 Jan 92,
ELCATECH INC WINSTON SALEM NC
Pagination or Media Count:
The objective of this Phase I effort, was to develop an amplified immunoassay which could detect botulinal neurotoxins A, B, E and F at concentrations equivalent to the mouse toxicity assay i.e. 5 pgml. Reasons for doing this included the likelihood that such an assay would be much shorter than the mouse toxicity hours rather than days, could be developed for field use, and would be substantially more economical than mouse bioassay. The approach which was to be applied to this problem, was the amplified immunoassay system developed by Elcatech. This system is based on the ultrasensitive measurement of coagulation-activating proteases by generation of a solid-phase enzyme-labeled fibrin matrix enzyme-linked coagulation assay, or ELCA. When a coagulation-activating protease is attached to an antigen or antibody, then the very sensitive detection of this labeled conjugate permits the very sensitive detection of the immune complexes formed in various assay protocols ELISA-ELCA . The general principle of this immunoassay is reflected in the Figure below.
APPROVED FOR PUBLIC RELEASE